

**PATENT**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**  
**(Case No. 10-817-US)**

<b>In re Application of:</b>	)	
	)	
<b>J. Crowley, et al.</b>	)	
	)	<b>Group Art Unit: 1651</b>
<b>Serial No.: 10/591,118</b>	)	
	)	<b>Examiner: Barnhart, L.E.</b>
<b>Filed: September 28, 2007</b>	)	
	)	<b>Confirm. No.: 7739</b>
<b>For: Process for Cell Culturing by Continuous )</b>		
<b>Perfusion and Alternating Tangential Flow</b>		

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, VA 22313-1450**

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. A Copy of the foreign reference is enclosed herewith. These references are also listed on the enclosed PTO Form 1449.

In the judgment of the undersigned, portions of the listed references may be material to the Examiner's consideration of the presently pending claims. However, the references have not been reviewed in sufficient detail to make any other representation and, in particular, no representation is intended as to the relative relevance between references, whether cited in this or prior statements. This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

**McDonnell, Boehnen, Hulbert & Berghoff LLP**  
**300 S. Wacker Drive, Suite 3100**  
**Chicago, IL 60606**  
**312-913-0001**

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of a national application; within three months of the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or before the mailing date of a first Office Action on the merits. 37 C.F.R. §1.97 (b)
- ☐ **after** three months of the filing date of a national application, or the date of entry into the national stage as set forth in 37 C.F.R. § 1.491 in an international application; or **after** the mailing date of a first Office Action on the merits, but **before** the mailing date of a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), and includes (37 C.F.R. § 1.97 (c):
- ☐ the Certification under 37 C.F.R. § 1.97(e) (see “Certification” below)

**OR**

- ☒ the fee of \$180 set forth in 37 C.F.R. § 1.17(p) (see “Fees” below).
- ☐ **after** a Final Action under 37 C.F.R. § 1.113 or a Notice of Allowance under 37 C.F.R. § 1.311 (whichever occurs first), but before, or simultaneously with, the payment of the issue fee, and includes the Certification under 37 C.F.R. § 1.97(e) (see “Certification” below), and the Petition Fee set forth in 37 C.F.R. § 1.17(i) (see “Fees” and “Method of Payment of Fees” below). Applicants hereby petitions for consideration of the Information Disclosure Statement submitted herewith and the accompanying references in examination of the subject patent application.

#### CERTIFICATION

- ☐ The **undersigned** hereby certifies that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
- ☐ The **undersigned** hereby certifies that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing the certification after making reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

FEES

- ☐ No fee is owed by the applicant(s).  
☒ The **IDS Fee of \$180.00** under 37 C.F.R. § 1.17(p) is enclosed herewith.

METHOD OF PAYMENT OF FEES

- ☒ Charge Deposit Account No. 13-2490 in the amount of \$180.00.

Please charge any underpayment or credit any overpayment in connection with this communication to Deposit Account No. 13-2490.

**US Patent Documents**

1. Wei-Shou Hu, et al. U.S. Patent No. 5,595,909, Issued on January 21, 1997.
2. Roland Varecka, et al. U.S. Patent No. 5,019,512, Issued on May 28, 1991.
3. Reiner Luttmann, et al., U.S. Published Patent Application No. US 2006-0014239, Published on January 19, 2006.

**Foreign Patent Documents**

4. German Patent No. DE 101 20 835, Published on November 7, 2002 "Batch method for preparing antibodies, useful as pharmaceuticals, by culturing cells with exchange of medium and removal of metabolic waste products" (English Abstract Included).
5. Japanese Patent No. JP 6485068, Laid open on March 30, 1989 "Cell Culture Apparatus" (English Version).

Respectfully submitted,

Date: /August 19, 2011/

/David S. Harper/  
David S. Harper, Ph.D.  
Registration No. 42,636

Telephone: 312-913-0001  
Facsimile: 312-913-0002

**McDonnell Boehnen Hulbert & Berghoff**  
300 South Wacker Drive  
Chicago, IL 60606

McDonnell, Boehnen, Hulbert & Berghoff LLP  
300 S. Wacker Drive, Suite 3100  
Chicago, IL 60606  
312-913-0001